INSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inspire Medical Systems Inc (INSP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish trend, with oversold technical indicators and significant uncertainties surrounding reimbursement and coding dynamics. Despite strong financial performance in the latest quarter, the lack of positive trading signals, neutral insider and hedge fund activity, and mixed analyst ratings suggest holding off on investment until the situation stabilizes or more positive catalysts emerge.
The stock is in a bearish trend with MACD negatively expanding (-0.201), RSI indicating oversold conditions (14.921), and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 50.9), with resistance levels far above the current price.
Revenue and net income showed significant YoY growth in Q4 2025, with net income up 286.36% and EPS up 301.72%. Gross margin improved to 86.59%.
Uncertainty around physician reimbursement and coding dynamics, including the impact of the -52 modifier, creates headwinds. Analysts have lowered price targets, and some have downgraded the stock. No recent positive trading trends or news catalysts.
In Q4 2025, revenue increased by 12.25% YoY to $269.08M, net income surged by 286.36% YoY to $136.09M, and EPS rose by 301.72% YoY to $4.66. Gross margin improved slightly to 86.59%.
Analysts are mixed, with some maintaining Buy ratings (e.g., Stifel, Mizuho) but lowering price targets, while others have downgraded the stock (e.g., Wolfe Research, Nephron Research). The stock faces near-term uncertainty due to reimbursement challenges and coding shifts.
